Jazz Pharmaceuticals Showcases Promising Phase 4 Results for Xywav® in Narcolepsy at SLEEP 2025, Underscoring Cardiovascular and Symptom Management Benefits Jazz Pharmaceuticals plc presented compelling new late-breaking data at the prestigious SLEEP 2025 conference, unveiling Phase 4 clinical results that…
Alnylam Secures European Commission Approval for AMVUTTRA® to Treat Cardiomyopathy in ATTR Amyloidosis Alnylam Pharmaceuticals, a global leader in RNA interference (RNAi) therapeutics, has received European Commission (EC) approval for an expanded indication of its RNAi drug AMVUTTRA® (vutrisiran). The…
Merck’s Pimicotinib Accepted for Priority Review in China, Offering Hope for Patients with TGCT Merck, a prominent global science and technology company, announced a significant milestone in its oncology portfolio as the Center for Drug Evaluation (CDE) under China’s National…
FDA Approves Merck’s ENFLONSIA™ to Protect Infants from Severe RSV Illness Merck operating as MSD outside the United States and Canada, has received a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting approval for ENFLONSIA™ (clesrovimab-cfor).…
Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to…
JCR Pharmaceuticals Celebrates 50 Years of Innovation with Global Website Launch That Reflects Its Expanding Reach and Human-Centric Mission As JCR Pharmaceuticals commemorates its 50th anniversary, the global specialty biopharmaceutical company is marking this major milestone with the launch of…
Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in collaboration with Otsuka Pharmaceutical Co., Ltd., has announced encouraging interim findings from…
Vertex Showcases Robust Clinical Data Supporting ALYFTREK® and the Critical Role of Sweat Chloride Reduction at 2025 European Cystic Fibrosis Conference New findings reinforce the value of CFTR modulation and the potential of ALYFTREK to enhance health outcomes and quality…
Sanofi Highlights Robust Pipeline of Innovations in Rare Blood Disorders at ISTH 2025 Sanofi is poised to take center stage at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH), set to be held in Washington, D.C.,…
AstraZeneca’s Fixed-Duration Calquence Regimen Gains EU Approval for First-Line Treatment of Chronic Lymphocytic Leukaemia AstraZeneca has received European Union (EU) approval for a fixed-duration combination therapy using its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) for the treatment of adult…
A Life-Course Approach to Immunization: Prioritizing Vaccination at Every Age to Unlock the Full Potential of Lifelong Health In a striking demographic milestone, the global population is undergoing a historic transformation: for the first time ever, the number of adults…
WHO Sounds Alarm on Imminent Collapse of Gaza Health System as Nasser and Al-Amal Hospitals Face Shutdown The World Health Organization (WHO) has issued an urgent warning about the imminent collapse of the healthcare system in the Gaza Strip, emphasizing…
